$IXHL is one of my biotech stocks to watch.
Incannex is trading around $2.97, with a market cap of roughly $37 million, despite reporting positive Phase 2 results across two programs. Its lead asset, IHL-42X for obstructive sleep apnea, has FDA Fast Track designation, a granted US patent, and has begun participant screening for the DReAMzz Phase 2 study.
The company also entered 2026 with more than $70 million in cash, received an additional A$6 million R&D refund, and expects further non-dilutive funding. That gives it considerably more financial flexibility than many micro-cap biotechs.
Incannex Healthcare +1
The opportunity is significant, but this remains a speculative clinical-stage investment. Trial execution, future results, dilution and regulatory outcomes are the main risks.
At its current valuation, I believe the risk-reward is compelling if Incannex continues delivering clinically and attracts a credible pharmaceutical partner.
High risk, high potential. Not financial advice.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
- EarlBoyle·08-05 20:02Fast Track plus $70M cash is why I’m still watching this closely. If DReAMzz enrollment stays on track, rerating feels fairLikeReport
- JoyceTobias·08-05 20:02Who said a 37M cap is cheap lol. I'm here for a real Phase 2 catalyst or buyout before then, cash just buys timeLikeReport